Opzelura (Ruxolitinib Phosphate) Patent Expiration, LOE Window & CMS Spending
Opzelura (Ruxolitinib Phosphate) by Incyte: FDA Orange Book core substance LOE 2028-12-12 (last listed 2041-05-05), 0 AB generics, $230.1M 2024 CMS Part D & Medicaid spend.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Incyte |
| FDA Application & Pathway | N215309 (NDA) |
| Exclusivity / Cliff Horizon | Long-Dated Protection (2036+) |
| Core Active-Ingredient LOE Date | 2028-12-12 |
| Last Listed Patent or Exclusivity Date | 2041-05-05 |
| Orange Book Patents (*PED Extensions) | 33 patents (11 *PED) |
| Active AB-Rated Generic Competitors | 0 |
| 2024 CMS Total Public Spend | $230.1M |
| 2024 Medicare Part D Spend | $105.9M |
| 2024 Medicaid Spend | $124.2M |
| Reported Wholesale Price Change (CA SB 17) | 0 statutory filings in 2023 to 2026 panel |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Incyte across sibling Meru public-data platforms.